Securities legislation in some Canadian provinces gives buyers the right to withdraw from a securities purchase agreement. This right may be exercised within two business days of receiving or receiving a prospectus and any changes. In several federal states, securities law also provides the purchaser with remedies for retraction or, in some jurisdictions, price or damages changes where the prospectus and any modifications are not delivered to the purchaser, provided that the appeals for resignation, price changes or damages are exercised by the purchaser within the time frame provided by the securities laws of the province of the province. However, these rights and remedies are not available to purchasers of common shares marketed under this prospectus, as the prospectus is not delivered to purchasers, as permitted by a decision document from the Financial Markets Authority of November 23, 2009. This agreement (as of May 8, 2018) is for the reciprocal agreement of yA II PN, LTD. (investor) and MICRONET ENERTEC TECHNOLOGIES, INC. (the “company”) be confirmed to terminate standBY EQUITY DISTRIBUTION AGREEMENT between the parties as of August 22, 2017 in the agreement collectively executed by the “SEDA” contract of November 17, 2017. LAVAL, QC , January 8 /PRNewswire-FirstCall/ – Labopharm Inc. (TSX: DDS); NASDAQ: DDSS) announced today that it has paid the $1 million deduction previously announced as part of its standby share distribution (SEDA) with YA Global Master SPV Ltd. (YA). As part of the drawdown, Labopharm issued 482,165 of its common shares to YA at a price of $2.07 per common share, net of the applicable discount. (All monetary data are denominated in Canadian dollars.) The forward-looking statements in this statement reflect management`s current views on future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those of forward-looking statements, all of which are difficult to predict and many of which are beyond BOS`s control.
These risk factors and uncertainties include, among other things, dependence on sales of one or a few large customers, uncertainty, that BOS is able to maintain current gross margins, the inability to track or anticipate technology and succeed in a highly competitive sector, the inability to maintain marketing and distribution agreements and expand our overseas markets, uncertainty about the rights prospects against BOS, the effects of exchange rate fluctuations, general global economic policy conditions, and the availability of financial resources for equity and debt refinancing; and the additional risks and uncertainties mentioned in the regular reports and registration statements of the BOS submitted to the United States.